🔮 OOTWOracle · All predictions · Odds sheet · Track record · Benchmark

DEA holds Schedule I for psilocybin/MDMA through 2026-10-11 (near-term checkpoint).

Predicted 2026-07-13 · Resolves 2026-10-11 · regulatory · USA

90%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

In the US, drugs are ranked in schedules from 1 to 5 based on how dangerous and useful the government thinks they are. Schedule I (the DEA — the Drug Enforcement Administration — drug police) means 'no accepted medical use and high abuse potential.' Both psilocybin and MDMA sit there now. Changing that requires the FDA to approve a drug first, and that hasn't happened, so the DEA can't legally move them.

Resolution rule: YES if, as of 2026-10-11, no final DEA rule rescheduling psilocybin or MDMA out of Schedule I has been published. Check federalregister.gov for DEA final rules. NO if such a rule appears. Check date: 2026-10-11.

Near-term version of the scheduling thesis. No pending final FDA approval exists that could trigger rescheduling before mid-October 2026, making this a high-confidence short-horizon resolution.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →